Fernanda F. Cruz
Federal University of Rio de Janeiro
111 Papers
284 Citations
Fernanda F. Cruz is an academic researcher from Federal University of Rio de Janeiro. The author has contributed to research in topics: Lung & Mesenchymal stem cell. The author has an hindex of 30, co-authored 97 publications. Previous affiliations of Fernanda F. Cruz include Rio de Janeiro State University & Ministry of Science, Technology and Innovation.
Chat about Author
Papers
Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.
Maroun Khoury,Jimena Cuenca,Fernanda F. Cruz,Fernanda F. Cruz,Fernando E Figueroa,Patricia R. M. Rocco,Patricia R. M. Rocco,Daniel J. Weiss +7 more
TL;DR: It is imperative to better comprehend the rationale and underlying data that both support and refute effectiveness of MSCs in respiratory virus infections, and to define the targeted patient population and potential cell therapy approaches for COVID-19.
238
Systemic Administration of Human Bone Marrow-Derived Mesenchymal Stromal Cell Extracellular Vesicles Ameliorates Aspergillus Hyphal Extract-Induced Allergic Airway Inflammation in Immunocompetent Mice
Fernanda F. Cruz,Fernanda F. Cruz,Zachary D. Borg,Meagan Goodwin,Dino Sokocevic,Darcy E. Wagner,Amy L. Coffey,Mariana Antunes,Mariana Antunes,Kristen L. Robinson,S. Alex Mitsialis,S. Alex Mitsialis,Stella Kourembanas,Stella Kourembanas,Kristen E. Thane,Andrew M. Hoffman,David H. McKenna,Patricia R. M. Rocco,Daniel J. Weiss +18 more
TL;DR: In this article, the authors demonstrate potent xenogeneic effects of conditioned media (CM) and extracellular vesicles (EVs) released by mesenchymal stromal cells (MSCs) derived from bone marrow and other sources are as effective as the MSCs themselves in mitigating inflammation and injury.
202
Anti-inflammatory properties of anesthetic agents
TL;DR: This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2017, which describes the current state of intensive care and emergency medicine in the UK.
Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial.
Patricia R. M. Rocco,Pedro L. Silva,Fernanda F. Cruz,Marco Antonio C. M. Junior,Paulo Fernando Guimarães Morando Marzocchi Tierno,Marcos de Assis Moura,Luis Frederico Gerbase De Oliveira,Cristiano Cleidson Lima,Ezequiel Aparecido Dos Santos,Walter Freitas Junior,Ana Paula Salles Moura Fernandes,Kleber G. Franchini,Erick Magri,Nara Franzin de Moraes,Jose Mario de Jesus Goncalves,Melanie Nogueira Carbonieri,Ivonise Sampaio Dos Santos,Natalia de Fatima Paes,Paula Veronica Martini Maciel,Raissa Prado Rocha,Alex Fiorini de Carvalho,Pedro Augusto Alves,José Luiz Proença Modena,Artur T. Cordeiro,Daniela Barreto Barbose Trivella,Rafael Elias Marques,Ronir Raggio Luiz,Paolo Pelosi,José Roberto Lapa e Silva +28 more
TL;DR: In this paper, a multicenter, randomized, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and fatigue) were enrolled.
150
The potential of mesenchymal stem cell therapy for chronic lung disease.
TL;DR: In clinical trials, MSC administration was safe, but associated with limited effects on clinical outcomes, and further studies are required to elucidate unresolved issues, including optimal MSC source and dose, route of administration, and frequency (single vs. multiple-dose regimens).
144